iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Bioventures 2014 L.P. Mpm sold 24,303 shares of iTeos Therapeutics stock in a transaction dated Monday, September 20th. The stock was sold at an average price of $27.49, for a total transaction of $668,089.47. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Bioventures 2014 L.P. Mpm also recently made the following trade(s):
- On Friday, September 17th, Bioventures 2014 L.P. Mpm sold 45,698 shares of iTeos Therapeutics stock. The stock was sold at an average price of $28.82, for a total transaction of $1,317,016.36.
- On Wednesday, September 15th, Bioventures 2014 L.P. Mpm sold 24,104 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.80, for a total transaction of $670,091.20.
Shares of ITOS stock opened at $26.81 on Tuesday. The stock has a market capitalization of $943.98 million, a P/E ratio of -13.08 and a beta of 2.43. The company has a 50 day moving average price of $26.16 and a 200 day moving average price of $26.37. iTeos Therapeutics, Inc. has a fifty-two week low of $17.43 and a fifty-two week high of $47.61.
Several hedge funds have recently made changes to their positions in the stock. RTW Investments LP grew its holdings in shares of iTeos Therapeutics by 157.2% in the first quarter. RTW Investments LP now owns 2,762,791 shares of the company’s stock valued at $94,432,000 after purchasing an additional 1,688,625 shares in the last quarter. BlackRock Inc. grew its holdings in shares of iTeos Therapeutics by 44.0% in the first quarter. BlackRock Inc. now owns 1,533,322 shares of the company’s stock valued at $52,409,000 after purchasing an additional 468,576 shares in the last quarter. Alliancebernstein L.P. grew its holdings in iTeos Therapeutics by 15.8% during the 2nd quarter. Alliancebernstein L.P. now owns 1,355,078 shares of the company’s stock worth $34,758,000 after acquiring an additional 185,077 shares in the last quarter. Citadel Advisors LLC grew its holdings in iTeos Therapeutics by 94.6% during the 2nd quarter. Citadel Advisors LLC now owns 994,396 shares of the company’s stock worth $25,506,000 after acquiring an additional 483,398 shares in the last quarter. Finally, Citigroup Inc. grew its holdings in iTeos Therapeutics by 1,125.1% during the 2nd quarter. Citigroup Inc. now owns 432,484 shares of the company’s stock worth $11,093,000 after acquiring an additional 397,181 shares in the last quarter. Hedge funds and other institutional investors own 83.69% of the company’s stock.
ITOS has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of iTeos Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 30th. SVB Leerink reduced their price target on shares of iTeos Therapeutics from $56.00 to $55.00 and set an “outperform” rating on the stock in a research note on Friday, August 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, iTeos Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $47.25.
About iTeos Therapeutics
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
See Also: Stock Symbol
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.